Compassion for patients and excitement for scientific breakthroughs have always motivated me as an oncologist. I feel privileged to treat patients with challenging diseases with an expanding array of effective therapies.
Medical Oncologist
Medical Oncology, Hematology, and Internal Medicine
University of North Carolina at Chapel Hill, Medical Oncology and Hematology; MD Anderson Cancer Center, Leukemia
The University of Texas Medical School at Houston
The University of Texas Medical School at Houston
University of Virginia
University of Virginia
Gastrointestinal Cancers and Genitourinary Cancers
A graduate of the University of Virginia Medical School, Dr. Sampat completed his Internal Medicine residency at the University of Texas – Houston and then spent one year completing a Leukemia fellowship at MD Anderson Cancer Center. He completed his Hematology & Medical Oncology fellowship at the University of North Carolina. Dr. Sampat’s education and training reflect a particular interest in advancing treatment options for patients with gastrointestinal malignancies. He has contributed to several publications and presentations in this field. Dr. Sampat stays active in the medical community through his memberships in associations such as the American Society of Clinical Oncology and the American Society of Hematology.
In his spare time, Dr. Sampat enjoys hiking, bicycling, and traveling.
Pleural effusions in patients with acute leukemia and myelodysplastic syndrome
Read MoreDoes pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Read MoreWhole Gene Expression Profiling in Ankylosing Spondylitis Shows Upregulation of Toll-Like Receptor 4 and 5
Read MoreCharacteristics of pericardial effusions in patients with leukemia.
Read MoreClofarabine: Emerging Role in Leukemias
Read MoreA Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
A safety and efficacy study of domvanalimab + zimberelimab combination therapy with and without chemotherapy in adult participants with advanced upper gastrointestinal tract malignancies
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (20-041-NCP)
A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer